Barclays Forecasts Strong Price Appreciation for Agilent Technologies (NYSE:A) Stock

Agilent Technologies (NYSE:A) had its target price increased by equities research analysts at Barclays from $145.00 to $150.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical research company’s stock. Barclays‘s target price points to a potential upside of 14.17% from the stock’s previous close.

Several other research firms have also weighed in on A. UBS Group reduced their price objective on shares of Agilent Technologies from $180.00 to $165.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Wolfe Research reaffirmed a “hold” rating on shares of Agilent Technologies in a research note on Tuesday, June 2nd. Morgan Stanley cut their target price on shares of Agilent Technologies from $180.00 to $160.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. Wells Fargo & Company lowered their price objective on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research report on Thursday, May 28th. Finally, HSBC dropped their price objective on Agilent Technologies from $180.00 to $165.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $161.27.

Agilent Technologies Trading Up 3.7%

NYSE A traded up $4.71 on Wednesday, reaching $131.38. The company had a trading volume of 257,172 shares, compared to its average volume of 2,262,858. The stock’s 50 day moving average is $121.94 and its 200-day moving average is $126.44. The stock has a market cap of $37.11 billion, a price-to-earnings ratio of 26.39, a PEG ratio of 2.25 and a beta of 1.26. The company has a quick ratio of 1.62, a current ratio of 2.10 and a debt-to-equity ratio of 0.43. Agilent Technologies has a 52 week low of $108.35 and a 52 week high of $160.27.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, May 27th. The medical research company reported $1.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.41 by $0.08. The firm had revenue of $1.83 billion for the quarter, compared to analysts’ expectations of $1.80 billion. Agilent Technologies had a return on equity of 24.33% and a net margin of 19.55%.The company’s revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the business earned $1.31 earnings per share. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. Equities analysts predict that Agilent Technologies will post 6 earnings per share for the current year.

Institutional Investors Weigh In On Agilent Technologies

Several institutional investors have recently added to or reduced their stakes in the stock. Bridgefront Capital LLC acquired a new stake in shares of Agilent Technologies in the 3rd quarter valued at about $1,323,000. Wellington Management Group LLP grew its holdings in shares of Agilent Technologies by 4.8% during the third quarter. Wellington Management Group LLP now owns 9,380,521 shares of the medical research company’s stock worth $1,203,990,000 after buying an additional 433,342 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Agilent Technologies by 4.3% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 599,581 shares of the medical research company’s stock worth $82,712,000 after buying an additional 24,687 shares in the last quarter. Champlain Investment Partners LLC raised its position in Agilent Technologies by 33.3% in the 3rd quarter. Champlain Investment Partners LLC now owns 895,770 shares of the medical research company’s stock valued at $114,972,000 after buying an additional 223,750 shares during the last quarter. Finally, Andra AP fonden raised its position in Agilent Technologies by 32.5% in the 3rd quarter. Andra AP fonden now owns 132,900 shares of the medical research company’s stock valued at $17,058,000 after buying an additional 32,600 shares during the last quarter.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.